Showing results (551-560 of 859) with videos related to
Sort By:
Pageof 86
Human Brain Mapping|December 1, 2000
Quantification of fMRI artifact reduction by a novel plaster cast head holderV Edward, C Windischberger, R Cunnington, et al.Journal of Hazardous Materials|September 19, 2020
Nitrate-N-mediated toxicological responses of Scenedesmus acutus and Daphnia pulex to cadmium, arsenic and their binary mixture (Cd/Asmix) at environmentally relevant concentrationsOlushola M Awoyemi, Seenivasan Subbiah, Anahi Velazquez, et al.Journal of Clinical Pharmacology|January 7, 2006
The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidaseReza Khosravan, Brian A Grabowski, Michael D Mayer, et al.The American Journal of Hospice & Palliative Care|August 14, 2012
Prospectively surveying health-related quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debilityS K Aggarwal, G T Carter, M D Sullivan, et al.Arzneimittel-Forschung|January 1, 1979
[Circadian fluctuations of pharmacokinetic parameters after oral administration of hexobarbital (author's transl)]P Altmayer, E Groterath, P W Lücker, et al.The American Review of Respiratory Disease|July 1, 1992
Ventilatory and metabolic responses to acute hyperoxia in newbornsJ P Mortola, P B Frappell, A Dotta, et al.European Journal of Drug Metabolism and Pharmacokinetics|January 26, 2002
Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomesE S Guns, P L Bullock, M L Reimer, et al.The British Journal of Surgery|August 1, 1995
Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantationC Miki, J D Harrison, B K Gunson, et al.Arzneimittel-Forschung|January 1, 1984
[Bioequivalence of phenylbutazone preparations following a single intramuscular administration]R Weyhenmeyer, E Dingler, R Lohaus, et al.American Journal of Therapeutics|January 22, 2005
Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairmentMichael D Mayer, Reza Khosravan, Laurent Vernillet, et al.Pageof 86